UK Advises mRNA and Protein Based COVID-19 Vaccines for Spring 2024 – Precision Vaccinations

(Precision Vaccinations News)

The Joint Committee on Vaccination and Immunisation (JCVI) todayannounced itsadvice to the U.K. Governmentfor the COVID-19 vaccine programme in spring 2024.

Similar to recent campaigns, the JCVI's advice issued on February 7, 2024, is to offer an updatedCOVID-19vaccine to those at high risk of serious disease and who are, therefore, most likely to benefit from vaccination.

JCVIadvises the following groups be offered vaccinationthis spring:

Professor Wei Shen Lim, Chair of COVID-19 immunization on theJCVI, said in a press release, "The COVID-19 spring program will continue to focus on those at greatest risk of getting seriously ill, who will benefit the most from a further vaccine dose."

"It is important that everyone eligible takes up the offer this spring."

Utilizing a deployment cost of 25 per vaccine, the non-standard cost-effectiveness assessment for booster vaccination in spring 2024 indicated that vaccination was likely cost-effective when offered to most people over 65 within the assumptions describing the most plausible projected scenario.

In addition to mRNA vaccines,Novavax Matrix-M adjuvanted COVID-19 vaccine (Nuvaxovid) andHIPRA bivalent COVID-19 vaccine (Bimervax) may be used as a booster dose for certain persons in 2024.

As of February 8, 2024,13COVID-19 vaccineshave been granted Emergency Use Listingby theWorld Health Organization. Recent additions includeSKYCovione andCORBEVAX.

Link:

UK Advises mRNA and Protein Based COVID-19 Vaccines for Spring 2024 - Precision Vaccinations

Related Posts
Tags: